StockNews.com began coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD – Free Report) in a report published on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Galmed Pharmaceuticals Stock Performance
NASDAQ GLMD opened at $4.20 on Tuesday. The business has a fifty day moving average price of $4.67 and a 200 day moving average price of $4.36. The company has a market cap of $21.19 million, a P/E ratio of -1.75 and a beta of 0.67. Galmed Pharmaceuticals has a one year low of $2.73 and a one year high of $23.80.
Galmed Pharmaceuticals (NASDAQ:GLMD – Get Free Report) last issued its earnings results on Wednesday, August 28th. The biopharmaceutical company reported $2.16 EPS for the quarter.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.
Featured Articles
- Five stocks we like better than Galmed Pharmaceuticals
- When to Sell a Stock for Profit or Loss
- The Outlook for Interest Rate Cuts Got Blown Out of the Water
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 High-Risk, High-Reward Micro-Cap Stocks You Shouldn’t Ignore
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 3 Bargain Stocks Positioned for Gains After Missing 2024’s Rally
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
